用于 CAR 或过继细胞疗法制造的白细胞去除术
Background:
Leukapheresis is a procedure to separate and collect white blood cells. It is the first step in a treatment called CAR (chimeric antigen receptor) T-cell therapy. CAR-T therapy may be offered to people when their cancer comes back. The collected T-cells are used to make a special version of T-cells called CARs. Researchers want to collect these cells from people who may become eligible for a CAR T-cell study in the future.
Objective:
To identify people who have a high likelihood to benefit from CAR T-cell therapy early in their disease course and collect and store a T-cell product.
Eligibility:
People ages 3-65 with a form of leukemia or lymphoma that has not been cured by standard therapy
Design:
Participants will be screened with medical history, physical exam, and blood and urine tests. Review of existing MRI, x-ray, pathology specimens/reports or CT images may be done.
On this study, participants will have leukapheresis. A needle will be placed into the arm. Blood will be collected and go through a machine. White blood cells will be taken out by the machine. The plasma and red cells will be returned to the participant through a second needle in the other arm. The procedure will take 4-6 hours. Some participants may have a central line (catheter) inserted which is needed to do the leukapheresis procedure, instead of the needles in the arms-especially if they are smaller. For a central line placement, a long thin tube is inserted through a small incision into the main blood vessel leading into the heart that would allow access to the blood to do the leukapheresis procedure.
Participants cells will be processed and frozen for future use in a CAR T-cell therapy study.
...
研究概览
详细说明
Background:
-
Leukapheresis is a necessary step to developing a "CAR therapy" or other adoptive cellular therapy products. There are numerous clinical trials underway in the NCI utilizing CAR therapy.
-
The purpose of this protocol is to develop a streamlined process whereby patients undergo apheresis for development of a CAR cell or other adoptive cell therapy product on a subsequent therapeutic clinical trial, which can be administered when the patient needs investigational therapies.
-
Emerging data suggests the critical importance of elements of the apheresis product in outcomes following adoptive cell therapy. Evaluation of methodologies to optimize timing and composition of the apheresis collection are imperative to the feasibility of manufacturing and remains an active area of investigations. Patient specific elements (e.g., presence of NK-cells/circulating leukemic blasts and/or inhibitory myeloid derived suppressor cells) along with other parameters of the apheresis product itself appear to influence efficacy and toxicity profiles of adoptive cell therapy.
-
Allowing for collection of the leukapheresis product in a protocol separate from the therapeutic protocol would allow for the best optimization of:
- Patient care and disease burden
- Timing and coordination of cell infusion
- Collection in patients with high-risk disease who have no current detectable disease but have a very high likelihood of relapse.
- Comprehensive evaluation of apheresis products will facilitate enhanced understanding of critical elements of the apheresis product in patients with cancer and how this may impact outcomes of adoptive cell therapy.
Objective:
To obtain via the leukapheresis process by which cells will be collected and stored for use in CCR CAR or other adoptive cell therapy clinical trials.
Eligibility:
Patients >=3 - <=65 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responding to at least one or more standard regimen.
Design:
-Once a patient is identified to be a future potential candidate for one of the NCI CAR or other adoptive cell therapy clinical trials, they will undergo leukapheresis, as estimated by recipient weight and target cell harvest dose in the Department of Transfusion Medicine
(DTM).
-No treatments, investigational or standard therapy will be administered on this protocol beyond those used to support the apheresis procedure.
研究类型
注册 (估计的)
联系人和位置
学习地点
-
-
Maryland
-
Bethesda、Maryland、美国、20892
- National Institutes of Health Clinical Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients 3-65 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responded to one or more standard regimens and/or deemed incurable by standard therapy and who meet all eligibility criteria are eligible to participate.
描述
-
INCLUSION CRITERIA:
-
Age: >= 3 and <= 65 years
-
Weight >= 15 kg
-
Confirmation of cancer diagnosis provided by disease-specific assessment (e.g., flow cytometry, PCR) or H&E verification.
-
Disease Status:
- Relapsed/refractory cancer that has failed at least one standard regimen and are not in remission at the time of leukapheresis, OR
- Previously treated patients without detectable disease at the time of leukapheresis but at high-relapse risk.
-
Potentially eligible for future NIH-CAR or other adoptive cell therapy based on the following:
-
Adequate performance status: Patients > 10 years of age: Karnofsky >= 50%; Patients <= 10 years of age: Lansky scale >= 50%
-
Adequate organ function:
- absolute neutrophil count >750/mcL*
- platelets >=30,000/mcL*
- total bilirubin <=2 X ULN (except in the case of subjects with documented Gilbert s disease > 3x ULN)
-
AST(SGOT)/ALT(SGPT)<=20 X institutional upper limit of normal for age and laboratory normal ranges
creatinine within age adjusted normal institutional limits (see below) OR
creatinine clearance >= 60 mL/min/1.73 m^2 for creatinine levels above institutional normal.
-
Age (Years): <=5; Maximum Serum Creatine (mg/dL): 0.8
-
Age (Years): 5 < age <= 10; Maximum Serum Creatine (mg/dL): 1.0
-
Age (Years): >10; Maximum Serum Creatine (mg/dL): 1.2
-
Cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusion.
- Patients, parents/guardians, legally authorized representative (LAR), or durable power of attorney must be able to give consent and sign the Informed Consent Document.
-
EXCLUSION CRITERIA:
- Transfusion refractory thrombocytopenia such that platelet count cannot be adequately supported with transfusions to be at >=30,000/mcL
- Active DIC, bleeding or coagulopathy which cannot be corrected with minimal intervention
- Rapidly progressive disease or hyperleukocytosis >= 50,000 blasts/mcL
- Symptomatic, uncontrolled or severe intercurrent illness that would compromise the ability to tolerate CAR or adoptive cell therapy-based toxicity
- Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met. Cytopenias deemed to be disease-related and not therapyrelated are exempt from this exclusion.
- Pregnant or nursing (lactating) individuals, where pregnancy is defined as the state of after conception and until the termination of gestation, confirmed by a positive hCG laboratory test at screening
- Active or latent hepatitis B or active hepatitis C, or any uncontrolled infection at screening
- Human Immunodeficiency Virus (HIV) infection at screening (The experimental treatments being evaluated depend upon an intact immune system. Patients who are HIV seropositive can have decreased immune competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities)
- Any patient that in the opinion of the investigator is not medically stable to undergo the leukapheresis procedure or will not comply with the visit schedules or procedures
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
1
Patients >/=3 - </=65 years of age, at least 15 kg, with relapsed/refractory cancer that has recurred after or not responded to at least one standard regimen |
Leukapheresis |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
fraction of subjects who can enroll on a CAR-T study within approximately 12 months of undergoing apheresis
大体时间:12 months after collection of apheresis product
|
number of subjects who enroll on a CAR-T study within approximately 12 months of undergoing apheresis |
12 months after collection of apheresis product
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
fraction of patients who experience a grade 4 toxicity associated with apheresis
大体时间:completion of apheresis procedure
|
number of patients who experience an unexpected grade 4 toxicity associated with apheresis |
completion of apheresis procedure
|
|
fraction of patients who can enroll on a CAR/adoptive cell therapy study within 12 months of undergoing apheresis by disease and type of CAR to be received.
大体时间:12 months after collection of apheresis product
|
number of patients who can enroll on a CAR/adoptive cell therapy study within 12 months of undergoing apheresis by disease and type of CAR to be received |
12 months after collection of apheresis product
|
合作者和调查者
调查人员
- 首席研究员:Srivandana Akshintala, M.D.、National Cancer Institute (NCI)
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 170137
- 17-C-0137
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All IPD recorded in the medical record will be shared with intramural investigators upon request.
IPD 共享时间框架
Clinical data available during the study and indefinitely.
IPD 共享访问标准
Clinical data will be made available via subscription to BTRIS and with the permission of the study PI.
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.